Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01252771 · ClinicalTrials.gov registry record · Phase 4

Phosphate Kinetic Modeling 2

A Phase 4 study of ESRD and Hyperphosphatemia, sponsored by Fresenius Medical Care North America.

Completed
Registry status
Phase 4
Development phase
81
Enrollment target
1
Study location

NCT01252771 is a Phase 4 study of ESRD and Hyperphosphatemia that has completed, run by Fresenius Medical Care North America. The registered enrollment target is 81 participants, below the 135-participant average among 13 other ESRD trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01252771, a Phase 4 study of ESRD and Hyperphosphatemia, has completed, sponsored by Fresenius Medical Care North America.

COMPLETED
Registry status
Phase 4
Development phase
81 participants
Enrollment target
1
Study location

Study Summary

The study aims to investigate the concept of computer based Phosphate Kinetic Modeling (PKM) in the hemodialysis patient population. This computerized algorithm model was developed as a tool to aid physicians in controlling a hemodialysis patient's phosphate level. Once a subject consents to participate in the study, the subject's dietary phosphate intake will be estimated by the modeling program and the appropriate dose of the phosphate binder calcium acetate (PhosLo) will be recommended accordingly. If necessary, the Ca++ concentration of the dialysate will be changed to remove any excess calcium absorbed as the result of an increase in the PhosLo prescription to control phosphorus.

Conditions Studied

Interventions

  • OTHER PKM Algorithm

Study Locations (1)

New York

  • Renal Research Insitutue - New York

Trial Details

FieldValue
Enrollment Target 81 participants
Start Date 2010-09
Est. Completion 2011-12
Phase Phase 4

What the Registry Record Tells You About NCT01252771

The ClinicalTrials.gov registry entry for NCT01252771 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 13 other ESRD trials with a reported enrollment target (40% lower). The listed sponsor is Fresenius Medical Care North America, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with ESRD appearing as the primary indexed condition, and to 1 intervention - of which PKM Algorithm is the first listed.

NCT01252771 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01252771 about?

NCT01252771 is a clinical study titled "Phosphate Kinetic Modeling 2". The study aims to investigate the concept of computer based Phosphate Kinetic Modeling (PKM) in the hemodialysis patient population. This computerized algorithm model was developed as a tool to aid physicians in controlling a hemodialysis patient's phosphate level. Once a subject consents to partici...

What is the current status of trial NCT01252771?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2010-09. Estimated completion is 2011-12.

What conditions does trial NCT01252771 study?

This clinical trial studies the following conditions: ESRD, Hyperphosphatemia.

What interventions are being tested in trial NCT01252771?

The interventions under investigation include: PKM Algorithm (OTHER).

Who is sponsoring clinical trial NCT01252771?

This trial is sponsored by Fresenius Medical Care North America, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01252771 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ESRD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.